Related Experiment Videos
Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions
B Remy1, G Deby-Dupont, M Lamy
1Department of Anaesthesia and Intensive Care Medicine, University of Liège, Belgium.
British Medical Bulletin
|March 1, 2000
Summary
Perfluorocarbon (PFC) emulsions and modified hemoglobin (Hb) solutions are being developed as oxygen carriers to address issues with homologous blood transfusions. These innovative blood substitutes are currently in clinical trials for various medical applications.
Area of Science:
- Biomedical Engineering
- Hematology
- Resuscitation Medicine
Background:
- Transfusion of homologous blood presents challenges, driving the need for artificial oxygen carriers.
- Perfluorocarbons (PFCs) and modified hemoglobin (Hb) solutions are emerging as potential alternatives.
Purpose of the Study:
- To evaluate the efficacy and safety of PFC emulsions and modified Hb solutions as blood substitutes.
- To assess their role in tissue oxygenation during medical procedures and emergencies.
Main Methods:
- PFCs administered as emulsions (e.g., Fluosol-DA 20%, Oxygent) deliver dissolved oxygen.
- Modified Hb solutions (e.g., diaspirin cross-linked hemoglobin - DCLHb) are engineered for improved oxygen affinity and half-life.
- Clinical trials are underway to analyze safety and efficacy.
Main Results:
- PFCs ensure tissue oxygenation during extreme hemodilution and are eliminated by the lungs.
- Modified Hb solutions, including DCLHb, show promise in preclinical and clinical studies for various surgical and emergency applications.
- Phase III trials are analyzing multicenter results for DCLHb.
Conclusions:
- PFC emulsions and modified Hb solutions represent significant advancements in artificial oxygen carriers.
- These blood substitutes offer potential solutions for oxygen delivery challenges in critical care and surgery.
- Ongoing clinical trials will determine their widespread adoption in medical practice.